LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Method Tracks T-Cells in HIV Patients

By LabMedica International staff writers
Posted on 24 Feb 2014
Image: Scanning electron micrograph of human immunodeficiency viruses attached to a human CD4 T-cell (Photo courtesy of Thomas Deerinck).
Image: Scanning electron micrograph of human immunodeficiency viruses attached to a human CD4 T-cell (Photo courtesy of Thomas Deerinck).
The determination of the precise lifespan of a human T-cell is challenging due to inability of standard techniques to distinguish between dividing and dying cells.

The duration of in vivo persistence can be measured by following a pool of T-cells that were "naturally" labeled with a single integrated clone of a replication-incompetent human immunodeficiency virus (HIV-1), called a provirus.

Scientist from the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) have discovered a novel method for tracking cluster of differentiation 4 (CD4+) T-cells in people infected with HIV. CD4+ T-cells are critical for immune defense against an array of pathogens and are a primary target of HIV. They utilized a combination of techniques to sequence/map an integration site of a unique provirus with a stop codon at position 42 of the HIV-1 protease. The defective virus had integrated into the genome of a single CD4+ T-cell.

In vitro reconstruction of this provirus into an infectious clone confirmed its inability to replicate. By combing cell separation and integration site-specific polymerase chain reaction (PCR) techniques, they were able to follow the fate of this single provirus in multiple T-cell subsets over a 20-year period. As controls, a number of additional integrated proviruses were also sequenced and analyzed with the ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems; Foster City, CA, USA).

This innovative method allows scientists to distinguish dividing cells from dying ones, something that has not been possible with existing labeling techniques, but is essential for studying how immune cells survive HIV infection. The replication-incompetent HIV-1 provirus was solely contained in the pool of effector memory (EM) CD4+ T-cell for 17 years. The percentage of the total EM CD4+ T-cells containing the replication-incompetent provirus peaked at 1% with a functional half-life of 11.1 months. In the process of sequencing multiple proviruses, they also observed high levels of lethal mutations in the peripheral blood pool of proviruses.

The scientists also observed in the blood cells of patients a higher frequency of defective HIV proviruses than what has been reported in previous work. Although these defective variants cannot produce an infectious virus, many retain the ability to generate small pieces of HIV, leading the investigators to speculate that these "foreign materials" within CD4+ T cells may play a key role in the ongoing immune activation that is characteristic of HIV infection, including in patients with "undetectable" virus in their blood. The study was published on January 31, 2014, in the journal AIDS.

Related Links:

National Institute of Allergy and Infectious Diseases 
Applied Biosystems


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
ESR Analyzer
TEST1 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more